BRAF and cancer: Consistent with this, in BRAF-mutated non-small cell lung cancer (NSCLC) and melanoma, YAP-dependent expression of BCL2L1 allows cancer cells to escape from apoptosis under BRAF- or MEK-targeting therapy [127], even though it has not been examined whether β-catenin is involved in this process.